Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies-Reference-Cited by-同舟云学术

Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies

Published:2016-10-07 Issue:1 Volume:176 Page:92-100
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Li Hong-Hua¹,Li Fei¹,Gao Chun-Ji¹,Huang Wen-Rong¹,Bo Jian¹,Dou Li-Ping¹,Wang Li-Li¹,Jing Yu²,Wang Lu¹,Li Wen-Jun¹,Yu Li¹,Liu Dai-Hong¹

Affiliation:

1. Chinese PLA General Hospital; Hematology Department; Beijing China

2. Hainan Branch of General Hospital of PLA; Department of Hematology; Sanya China

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14331/fullpdf

Reference21 articles.

1. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria;Arai;Blood,2011

2. Haploidentical G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update;Arcese;Bone Marrow Transplantation,2015

3. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse;Aversa;Journal of Clinical Oncology,2005

4. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies;Di Bartolomeo;Blood,2013

5. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report;Filipovich;Biology of Blood and Marrow Transplantation,2005

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients Beyond the Optimal Range of rATG-AUC Still Benefit from the Targeted Dosing Strategy in Unmanipulated Haplo-PBSCT;Transplantation and Cellular Therapy;2024-08

3. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study;Annals of Hematology;2023-11-06

4. Targeted dosing of anti‐thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single‐arm, phase 2 trial;American Journal of Hematology;2023-09-14

5. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors;Transplantation and Cellular Therapy;2022-11